Secondly, it is of the utmost importance to ascertain whether the VAF in JAK2 V617F plays a role in MPN-SVT, not only in diagnosis and prognosis, but also in achieving thrombosis-related outcomes (e.g., recanalization, recurrence). This evidence concerns the gene JAK2 and myeloproliferative disorder.